support@mellalta.com   +1 (304) 306-0723

Daiichi Sankyo’s Well-Written Market Positioning Strategy for DS-1062 (Antibody Drug Conjugate) in TNBC and NSCLC Landscape

Daiichi Sankyo’s DS-1062 is a TROP2-directed antibody drug conjugate (ADC), designed using Daiichi Sankyo’s proprietary DXd ADC technology with the highest development stage of Phase I. We, Mellalta Meets, unveil the Daiichi’s strategies with the […]

Read More

Get In Touch

Let's keep the conversation going